Alterity Therapeutics Ltd (ASX: ATH) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Alterity Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $9.81 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.44 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return -70.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Alterity Therapeutics Ltd (ASX: ATH)
    Latest News

    A drawing of a white rocket streaking up, indicating a surging share pirce movement
    Healthcare Shares

    Why the Alterity (ASX:ATH) share price is skyrocketing 42% today

    The Alterity Therapeutics (ASX: ATH) share price is skyrocketing after the company's release of positive results for its lead compound.

    Read more »

    A medical researcher works on a bichip, indicating share price movement in ASX tech companies
    Share Market News

    Here's why the Alterity Therapeutics (ASX:ATH) share price blasted 20% higher today

    The Alterity Therapeutics share price is having a monster day, posting a gain of more than 20%. Let's take a…

    Read more »

    miniature rocket breaking out of golden egg representing rocketing share price
    Share Market News

    Why Alterity Therapeutics (ASX:ATH) share price has surged up 27% today

    The Alterity Therapeutics Ltd (ASX: ATH) share price has up 27% today after its neurodegenerative patent received approval in the…

    Read more »

    falling asx share price represented by woman making sad face
    Share Market News

    Alterity (ASX:ATH) share price lower on completed placement

    The Alterity Therapeutics Ltd (ASX: ATH) share price has been falling today following a release of a completed capital raise.

    Read more »

    ⏸️ Investing

    Why Alterity Therapeutics' share price has rocketed 96% in 2 days

    The Alterity share price has almost doubled in 2 days on the back of new data.

    Read more »

    Investor riding a rocket blasting off over a share price chart
    Share Market News

    Alterity Therapeutics share price rockets 70% on new data

    The Alterity share price has surged more than 70% in early trade after the company released new clinical data regarding…

    Read more »

    Share Market News

    Why Etherstack and these shares were the most traded on the ASX last week

    Etherstack PLC (ASX:ESK) and Afterpay Ltd (ASX:APT) shares were among the most traded shares on the ASX last week. Here's why...

    Read more »

    ATH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Alterity Therapeutics Ltd

    Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

    ATH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    30 Nov 2023 $0.00 $0.00 0.00% 829,802 $0.00 $0.00 $0.00
    29 Nov 2023 $0.00 $0.00 0.00% 9,666,534 $0.00 $0.00 $0.00
    28 Nov 2023 $0.00 $0.00 0.00% 66,837,337 $0.00 $0.00 $0.00
    27 Nov 2023 $0.00 $0.00 0.00% 2,134,427 $0.00 $0.00 $0.00
    24 Nov 2023 $0.00 $0.00 0.00% 1,241,482 $0.00 $0.01 $0.00
    23 Nov 2023 $0.00 $0.00 0.00% 1,632,982 $0.00 $0.00 $0.00
    22 Nov 2023 $0.00 $0.00 0.00% 30,199,429 $0.01 $0.01 $0.00
    17 Nov 2023 $0.01 $0.00 0.00% 3,809,408 $0.01 $0.01 $0.01
    16 Nov 2023 $0.01 $0.00 0.00% 503 $0.01 $0.01 $0.01
    15 Nov 2023 $0.01 $0.00 0.00% 1,243,537 $0.01 $0.01 $0.01
    14 Nov 2023 $0.01 $0.00 0.00% 734,901 $0.01 $0.01 $0.01
    13 Nov 2023 $0.01 $0.00 0.00% 4,621,712 $0.01 $0.01 $0.01
    10 Nov 2023 $0.01 $0.00 0.00% 324,131 $0.01 $0.01 $0.01
    09 Nov 2023 $0.01 $0.00 0.00% 100,080 $0.01 $0.01 $0.01
    08 Nov 2023 $0.01 $0.00 0.00% 2,110,824 $0.01 $0.01 $0.01
    07 Nov 2023 $0.01 $0.00 0.00% 18,959 $0.01 $0.01 $0.01
    06 Nov 2023 $0.01 $0.00 0.00% 71,785 $0.01 $0.01 $0.01
    03 Nov 2023 $0.01 $0.00 0.00% 54,220 $0.01 $0.01 $0.01
    01 Nov 2023 $0.01 $0.00 0.00% 406,555 $0.01 $0.01 $0.01

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    14 Dec 2022 Geoffrey Kempler Expiry 5,000,000 $50,000
    Options expired.
    14 Dec 2022 Brian Meltzer Expiry 1,250,000 $12,500
    Options expired.
    14 Dec 2022 Peter Marks Expiry 1,250,000 $12,500
    Options expired.
    14 Dec 2022 Lawrence Gozlan Expiry 1,250,000 $12,500
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Geoffrey Paul Kempler Non-Executive ChairmanNon-Executive Director Jun 2005
    Mr Kempler has experience in investment and business development and has been responsible for the implementation of our strategic plan and the commercialisation of our technology. Mr. Kempler was appointed Chairman of Ausbiotech, Australia's biotechnology organization, on 8 November 2021 and also sits on the Monash Institute of Cognitive and Clinical Neurosciences (MICCN) Industry Advisory Board at the Turner Institute of Brain and Mental Health at Monash University, where he is also an Adjunct Senior Lecturer.
    Mr Brian Derek Meltzer Non-Executive Director Dec 1999
    Mr Meltzer has spent 25 years in investment banking. His breadth of expertise includes major property transactions, corporate advisory, corporate finance, management buyouts, venture capital and large-scale syndications. He has held a number of Board and Board Advisory roles for private companies in the human resources, health and wellness, aged care, software, entertainment and finance sectors, including Director of a federal government licensed Innovation Investment Fund. In 2015 he acquired a corporate health division of an American multinational then grew it five-fold before selling it in 2021 to the subsidiary of a Canadian multinational. Mr. Meltzer is also a Director of the Australia-Israel Chamber of Commerce and Chairman of Independence Australia, a social enterprise.
    Mr Peter Ashley Marks Non-Executive Director Jul 2005
    Mr. Marks is currently Chairman of Newburyport Partners, a boutique corporate and capital markets advisory firm specializing in advising and raising capital for a range of small to mid-cap companies. Mr. Marks is also a non- executive director of Electriq-Global Ltd, an unlisted public company developing a novel and safe hydrogen fuel storage and transportation system. Mr. Marks was employed by KPMG Corporate Finance Ltd (Australia), where he rose to the position of Director and was responsible for heading up the equity capital markets group in Melbourne. Mr. Marks served as Director of Corporate Finance at Burdett Buckeridge & Young Ltd in their Melbourne offices, , he held senior corporate finance position at Barings Securities Ltd, and from July 1985 until July 1988, he served as an Associate Director of McIntosh Securities, now Merrill Lynch Australia. In his roles with these various financial institutions, Mr. Marks was responsible for advising a number of listed and unlisted companies on issues ranging from corporate and company structure, valuations, business strategies, acquisitions and international opportunities.
    Mr Lawrence Gozlan Non-Executive Director Aug 2011
    Mr Gozlan, a biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. Scientia Capital was founded to provide high level expertise and to manage investments for high-net worth individuals, family offices and institutional investors wanting exposure to the biotechnology industry. Prior to this, Mr. Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (the Queensland Investment Corporation), an investment fund with over A$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd and gained senior corporate finance experience advising life sciences companies at Deloitte.
    Mr Phillip Hains Company Secretary May 2014
    Dr David Stamler Chief Executive Officer Jan 2021
    David Stamler Chief Executive Officer
    Kathryn J.E. Andrews Chief Financial Officer
    Phillip Hains Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 1,289,787,764 52.86%
    Jagen Pty Ltd 38,556,497 1.58%
    Capuano Nominees Pty Ltd <The Hartman Investment A/C> 28,250,000 1.16%
    Mr Anurag Pandey 21,042,904 0.86%
    Mr Huy Nguyen and Ms Rebecca Nguyen <Huy Nguyen Sf A/C> 19,518,436 0.80%
    Ms Elif Ceren Gunes 18,000,000 0.74%
    Andrew Mark Wilmot Seton 17,627,333 0.72%
    Rentuk Shore Pty Ltd 15,641,719 0.64%
    Mr Buu Lan Au 15,489,010 0.63%
    Citicorp Nominees Pty Limited 15,454,323 0.63%
    Baywick Proprietary Limited <The Retail Discretionary A/C> 14,165,000 0.58%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 13,136,625 0.54%
    Miss Jia Lu 12,418,724 0.51%
    Mrs Kate Elizabeth Schroeter 12,111,001 0.50%
    Mr David John Southon <Southon Family A/C> 10,704,781 0.44%
    Fagan Harris Pty Ltd <Fagan Harris Super Fund A/C> 10,500,000 0.43%
    Mr Jason Khoo 10,000,000 0.41%
    Mr Benjamin Woolvett 9,628,571 0.39%
    Bnp Paribas Noms Pty Ltd <Drp> 8,158,006 0.33%
    Mr Minh Huy Lam 8,000,000 0.33%